SCHEMBL5361022

SCHEMBL5361022

CCOC(=O)C(Cc1ccc(OCc2ccccc2)c(OC)c1)(NC(C)=O)C(=O)OCC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.65
RECQL P46063 1/20 0.65
MTNR1A P48039 2/20 0.55
MTNR1B P49286 2/20 0.55
APP P05067 2/20 0.53
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 2/20 0.49
PKM P14618 1/20 0.49
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPRB P23467 1/20 0.48
ACP1 P24666 1/20 0.48
MAPK1 P28482 1/20 0.48
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2688605 0.88 ALDH1A1 (0.64) ALDH1A1RECQLSMN1; SMN2MEN1KMT2A
SCHEMBL5361031 0.82 MTNR1A (0.50) ALDH1A1RECQLMTNR1AMTNR1BAPP
SCHEMBL5366575 0.82 ALDH1A1 (0.62) ALDH1A1RECQLMEN1KMT2AKDM4E
SCHEMBL27395266 0.80 ALDH1A1 (1.00) ALDH1A1RECQLAPPMEN1KMT2A
SCHEMBL5363739 0.80 ALDH1A1 (0.60) ALDH1A1RECQLSMN1; SMN2MEN1KMT2A
SCHEMBL5365516 0.80 ALDH1A1 (0.60) ALDH1A1RECQLMEN1KMT2AKDM4E
SCHEMBL11282039 0.80 ALDH1A1 (0.60) ALDH1A1RECQLNPC1RAB9ASMN1; SMN2
SCHEMBL20483556 0.79 APP (0.52) ALDH1A1MTNR1AMTNR1BAPPNPC1
SCHEMBL5369771 0.78 ALDH1A1 (0.57) ALDH1A1RECQLAPPMEN1KMT2A
SCHEMBL10278608 0.78 ALDH1A1 (0.56) ALDH1A1RECQLHPGDSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123532-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2007-05-31 US disclosed
US-7166598-B2 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome ASTELLAS PHARMA INC. (JP) 2007-01-23 US disclosed
EP-1140924-B1 PIPERAZINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2006-03-22 EP disclosed
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2006-01-19 US disclosed
EP-1140924-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed
WO-2000035915-A1 PIPERAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014948-A1 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals PKD2, TAC3, PKD1 ALDH1A1 2048/4885RECQL 4515/4885MTNR1A 221/4885
US-20070123532-A1 PIPERAZINE DERIVATIVES PKD2, SSTR5, IL5 ALDH1A1 1846/4885RECQL 4681/4885MTNR1A 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.